Daxor Corp (DXR)
NASDAQ:DXR
Want to see DXR full AI Analyst Report?
Top Page
Daxor
(NASDAQ:DXR)
Select Model
Select Model
Rating:64Neutral
Price Target:
$12.50
▲(32.56% Upside)
Action:Reiterated
Date:04/30/26
The score is driven primarily by mixed financial performance: a very strong, low-debt balance sheet offsets volatile revenues and weak/uneven cash generation. Technicals are supportive with improving momentum, and valuation looks inexpensive on P/E, though there is no dividend yield.
Positive Factors
Balance Sheet Strength
Extremely low leverage and a sizable equity cushion materially reduce financial risk and provide enduring flexibility. Over 2-6 months this supports continued R&D, service commitments, and the ability to withstand revenue volatility without forcing distress sales or urgent external financing.
Negative Factors
Weak Cash Generation
Repeated negative operating and free cash flow indicate earnings do not reliably convert to cash. Over the coming months this limits self-funding for working capital, capital needs, and sales expansion, raising execution risk and potential need for external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Extremely low leverage and a sizable equity cushion materially reduce financial risk and provide enduring flexibility. Over 2-6 months this supports continued R&D, service commitments, and the ability to withstand revenue volatility without forcing distress sales or urgent external financing.
Read all positive factors
Daxor (DXR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
N/A
Dividend YieldN/A
Average Volume (3M)1.99K
Price to Earnings (P/E)2.0
Beta (1Y)0.68
Revenue GrowthN/A
EPS Growth1682.38%
CountryUS
Employees37
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)1.82
Shares Outstanding5,827,225
10 Day Avg. Volume865
30 Day Avg. Volume1,994
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.60
Price to Sales (P/S)146.07
P/FCF Ratio-121.66
Enterprise Value/Market Cap10.00T>
Enterprise Value/Revenue334.54
Enterprise Value/Gross Profit-582.32
Enterprise Value/Ebitda5.27
Forecast
1Y Price Target
$22.50Price Target Upside138.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.21
Revenue Forecast (FY)$11.90M
Daxor Business Overview & Revenue Model
Company Description
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective...
How the Company Makes Money
Daxor makes money primarily by commercializing its blood volume measurement platform and related services. Key revenue streams include: (1) sales or placements of BVA blood volume analysis systems and associated components used by hospitals and cl...
Daxor Earnings Call Summary
Earnings Call Date:Mar 06, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Aug 20, 2026
Earnings Call Sentiment Positive
The earnings call presented a robust performance with significant revenue growth, successful strategic acquisitions, and expanded clinical partnerships. Despite a delay in FDA approval and a decrease in unrealized appreciation, the company showcased strong momentum and promising developments for the future.Positive Updates
Increase in Net Asset Value
Daxor's net assets increased from $34,010,384 in 2023 to $36,789,893 in 2024, reflecting a rise in net asset value per share from $7.08 to $7.25.
Negative Updates
Net Decrease in Unrealized Appreciation
There was a net decrease of $1,148,350 in the unrealized appreciation on investments due to the sale of positions with prior significant unrealized gains.
Read all updates
Q4-2024 Updates
Positive
Negative
Increase in Net Asset Value
Daxor's net assets increased from $34,010,384 in 2023 to $36,789,893 in 2024, reflecting a rise in net asset value per share from $7.08 to $7.25.
Read all positive updates
Company Guidance
During the Daxor Corporation Conference Call for the 2024 fiscal year, management provided several key financial and operational metrics. As of December 31st, 2024, the company's net assets increased to $36,789,893 or $7.25 per share, compared to $34,010,384 or $7.08 per share at the end of 2023. The company's net income included net dividend income of $104,115 and net realized gains on investments of $1,359,163, offset by a net decrease in unrealized appreciation of $1,148,350. The company invested $1,614,124 into its operating division for research and development, sales, and production facilities in anticipation of a 2025 product launch. Additionally, Daxor achieved a cash flow breakeven in early 2025, excluding costs related to stock-based compensation, depreciation, amortization, or CapEx. Revenue increased by 116.5% from 2023 to 2024, with a further year-on-year increase of over 100% in the first two months of 2025. The company also reported significant clinical progress with the adoption of its Blood Volume Analyzer (BVA) technology across various medical disciplines, laying the groundwork for further growth and innovation in healthcare solutions.Daxor Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
84
Very Positive
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 503.42K | 2.13M | 34.59M | -353.36K | -2.62M |
| Gross Profit | 188.74K | 2.13M | 34.41M | -1.44M | -3.62M |
| EBITDA | 9.19M | 2.06M | 329.74K | 6.11M | 4.75M |
| Net Income | 9.17M | 536.33K | 280.64K | 5.18M | 4.75M |
Balance Sheet | |||||
| Total Assets | 46.01M | 36.63M | 34.87M | 30.26M | 24.98M |
| Cash, Cash Equivalents and Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 | 710.70K |
| Total Debt | 112.00K | 729.97K | 755.66K | 1.23M | 3.02M |
| Total Liabilities | 122.59K | 840.30K | 858.76K | 1.29M | 3.83M |
| Stockholders Equity | 45.89M | 35.79M | 34.01M | 28.97M | 21.15M |
Cash Flow | |||||
| Free Cash Flow | -604.42K | 25.69K | -3.66M | -769.30K | -2.76M |
| Operating Cash Flow | -604.42K | 25.69K | -3.66M | -769.30K | -2.76M |
| Investing Cash Flow | 1.18M | 1.94M | 2.75M | 2.69M | 74.76K |
| Financing Cash Flow | -570.94K | -25.69K | 3.66M | 58.60K | 2.85M |
Daxor Technical Analysis
Neutral
9.43
Price Trends
11.00
Negative
12.11
Negative
11.83
Negative
Market Momentum
-0.44
Negative
48.02
Neutral
78.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DXR, the sentiment is Neutral. The current price of 9.43 is below the 20-day moving average (MA) of 9.74, below the 50-day MA of 11.00, and below the 200-day MA of 11.83, indicating a neutral trend. The MACD of -0.44 indicates Negative momentum. The RSI at 48.02 is Neutral, neither overbought nor oversold. The STOCH value of 78.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DXR.
Daxor Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $180.39M | 9.98 | 29.10% | ― | 16.39% | 29.86% | |
65 Neutral | $3.65B | 25.02 | 8.95% | ― | 11.34% | 12.26% | |
64 Neutral | ― | 1.96 | 22.50% | ― | ― | 1682.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $28.17M | -5.14 | -173.86% | ― | 3.99% | -17.45% | |
46 Neutral | $22.77M | 21.30 | -534.91% | ― | 39.88% | 64.70% |
* Healthcare Sector Average
DXR
Daxor
10.30
3.00
41.03%
MMSI
Merit Medical Systems
62.62
-34.39
-35.45%
PDEX
Pro-Dex
57.44
14.10
32.53%
MLSS
Milestone Scientific
0.35
-0.54
-60.67%
FEMY
Femasys
0.38
-0.67
-63.71%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.